Recombinant Human LILRA4/CD85g/ILT7 Protein, CF

When Recombinant Human LILRA4/CD85g/ILT7 is coated at 1μg/mL, Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (Catalog # 914-AN) binds with an ED50 of20-120 ng/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human LILRA4/CD85g/ILT7 Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human LILRA4/CD85g/ILT7 is coated at 1 μg/mL, Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (Catalog # 914-AN) binds with a typical ED₅₀ of 20-120 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived human LILRA4/CD85g/ILT7 protein
  Glu24-Asn446, with a C-terminal 6-His tag
• Accession #: P59901
• N-terminal Sequence: Glu24
• Protein/Peptide Type: Recombinant Proteins
• Gene: LILRA4
• Purity: >90%, by SDS-PAGE with silver staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 47 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-73 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE with silver staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human LILRA4/CD85g/ILT7 Protein, CF

• CD85 antigen-like family member G
• CD85g antigen
• CD85g
• ILT7
• ILT-7
• ILT7MGC129598
• Immunoglobulin-like transcript 7
• leukocyte immunoglobulin-like receptor subfamily A member 4
• leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 4
• leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), member4
• LILRA4
• MGC129597

Background

LILRA4, also known as ILT7 and CD85g, is an approximately 60-70 kDa variably glycosylated transmembrane protein that regulates immune cell activation (1). Mature human LILRA4 consists of a 423 amino acid (aa) extracellular domain (ECD) with four immunoglobulin-like domains, a 21 aa transmembrane segment, and a 32 aa cytoplasmic domain (2). Alternative splicing generates an additional isoform that lacks the signal peptide and a portion of the first Ig-like domain. LILRA4 is expressed on plasmacytoid dendritic cells (pDC) but is down-regulated in response to TLR9 signaling (3-5). Antibody mediated crosslinking of LILRA4 on pDC inhibits the production of type I interferons following TLR7 or TLR9 stimulation (3, 4, 6). It also blocks the up-regulation of CCR7 but enhances the up-regulation of Integrin  beta 7 on TLR7/9-stimulated pDC (6). LILRA4 associates with the ITAM-containing adaptor protein Fc epsilon RI gamma (3, 4, 6), and this complex binds to cell surface BST2/Tetherin which is expressed on monocytes, plasmacytoid and myeloid dendritic cells, B cells, and activated CD4⁺ and CD8⁺ T cells (5, 8). This interaction inhibits the TLR-induced pDC production of type I interferons, IL-6, and TNF-alpha (8).

1. Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
2. Young, N.T. et al. (2001) Immunogenetics 53:270.
3. Cho, M. et al. (2008) Int. Immunol. 20:155.
4. Cao, W. et al. (2006) J. Exp. Med. 203:1399.
5. Tavano, B. et al. (2013) J. Immunol. 190:2622.
6. Tsukamoto, N. et al. (2009) Clin. Cancer Res. 15:5733.
7. Tavano, B. and A. Boasso (2014) PLoS ONE 9:e89414.
8. Cao, W. et al. (2009) J. Exp. Med. 206:1603.

Bioinformatics

• Gene Symbol: LILRA4
• Uniprot:
  • P59901(Human)